Oncotelic Therapeutics, Inc. OTLC

Company Overview

Oncotelic Therapeutics, Inc. (OTC Markets: OTLC) is a clinical-stage biotechnology company focused on the development of therapeutics targeting oncology, rare diseases, and infectious diseases. The company’s primary activities center on advancing drug candidates through clinical development, licensing intellectual property, and pursuing strategic collaborations within the biopharmaceutical sector. Its core pipeline has included RNA-based therapeutics, immuno-oncology programs, and compounds intended for difficult-to-treat cancers such as glioblastoma and pancreatic cancer. The company operates within the broader biotechnology and pharmaceutical development industries, with a particular emphasis on translational medicine and precision therapeutics.

A principal asset associated with the company has been OT-101 (trabedersen), an antisense RNA therapeutic designed to inhibit transforming growth factor beta 2 (TGF-β2), a target associated with tumor progression and immune suppression. Oncotelic has also explored programs involving artificial intelligence-driven drug discovery, mRNA technologies, and infectious disease applications through affiliated entities and partnerships. The company evolved through a series of mergers, licensing arrangements, and asset acquisitions involving oncology-focused biotechnology businesses, positioning itself as a diversified clinical-stage therapeutics developer with a focus on high unmet medical need indications.